secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001438533-24-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Q1: FILSPARI sales $19.8M; FDA Priority Review for full approval by Sept 5
--------------------------------------------------------------------------------

- Net product sales $40.0M (Q1 2024), up from $24.2M YoY, driven by FILSPARI launch.
- FILSPARI net sales $19.8M; 511 new PSFs in Q1, total 1,963 since launch.
- FDA granted Priority Review for sNDA to convert accelerated approval to full approval for IgAN; PDUFA Sept 5, 2024.
- Net loss $136.1M ($1.76/share) vs $86.3M loss in Q1 2023, including $65M IPR&D milestone for pegtibatinase.
- Cash, equivalents, and securities $441.0M as of March 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000019/0001438533-24-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000019/tvtx-20240506.htm
  HTML page:      https://secwatch.observer/filing/0001438533-24-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer